Stronger CMV treatment for lung transplant recipients
Treatments studied
Part of Immune system & allergy, Infections, Lungs & breathing clinical trials.
This trial tests adding a drug called letermovir to standard antiviral therapy for lung transplant patients with CMV infection. The goal is to see if the combination helps clear the virus faster and more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a lung transplant.
- You have an active CMV infection with a viral load of at least 1000 IU/mL.
- You are about to start or have just started (within the last 72 hours) standard antiviral treatment for CMV.
- You do not have severe kidney failure (creatinine clearance below 15 mL/min or on dialysis).
- You do not have severe liver disease (Child-Pugh Class C).
- You are not taking cyclosporin, pimozide, or ergot alkaloids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two medications, letermovir and valganciclovir, to see which works better at preventing CMV infection in people who have received a kidney transplant and have previously been exposed to the virus. Taking part may help reduce the risk of a serious infection after transplant.
This trial tests whether taking letermovir for a longer time can prevent CMV (a common virus) from reactivating in adults with certain risk factors after a donor stem cell transplant. If you're preparing for your first transplant and have a high-risk donor or conditioning, this study may be an option.
This trial tests whether the drug letermovir can prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. It is for adults who are CMV-positive and have not yet had a CMV infection.
This study tests a new drug called letermovir, given after a lung transplant, to see if it prevents CMV infection better than the current standard drug, valganciclovir. If you're at high risk for CMV, this trial could help protect you from this common post-transplant infection.
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
This trial tests whether a drug called letermovir can safely treat CMV infection in people who have had a kidney or pancreas transplant. It is for those who are at high risk for CMV and whose own immune system cannot fight the virus.
Hear when a new CMV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.